According to those guidelines, patients with stages 3–4 CKD with an estimated glomerular filtration rate (eGFR) of ≥ 25– < 60 mL/min/1.73 m2 and moderately or severely increased albuminuria should be treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), if possible [5–7]. Here, ACE is linked to chronic kidney disease.